"We ended an outstanding year with a lot of momentum across all facets of our business and have achieved or exceeded all of the stated 2022 ELEVATE! milestones we set out at the beginning of 2022," commented Erik Holmlin, PhD, president and chief executive officer of Bionano. "Bionano issued revenue guidance for the first time in 2022, and we not only came in at the high end of our guidance each quarter, but we exceeded our total 2022 guidance range. We were also pleased to see an incredible uptick in overall awareness and adoption of optical genome mapping across the globe."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
- Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
- Bionano Genomics initiated with an Outperform at Scotiabank
- Bionano Genomics assumed with a Buy at BTIG
- Multi-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in Leukemia
